Ken Griffin Ngm Biopharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$1.17 - $1.92 $819 - $1,344	700 Added 700.0%	800 $1,000
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $180 - $393	-300 Reduced 75.0%	100 $0
Q3 2023 Nov 14, 2023	SELL	$1.05 - $3.37 $2,100 - $6,740	-2,000 Reduced 83.33%	400 $0
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $5,124 - $9,513	2,100 Added 700.0%	2,400 $6,000
Q1 2023 May 15, 2023	SELL	$3.72 - $5.4 $326,616 - $474,120	-87,800 Reduced 99.66%	300 $1,000
Q4 2022 Feb 14, 2023	SELL	$3.41 - $12.93 $51,832 - $196,536	-15,200 Reduced 14.71%	88,100 $442,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $334,894 - $470,022	26,600 Added 34.68%	103,300 $1.35 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.